Science News from #ISC24

That's a Wrap!

Tudor Jovin, MD, FAHA, and Lauren Sansing, MD, PhD share their top picks from all the #ISC24 activities, and encourage viewers to attend the International Stroke Conference next year, February 5-7, 2025 in Los Angeles.

MOST

Multi-Arm Optimization of Stroke Thrombolysis Trial
Opeolu M Adeoye, Washington Univ, Saint Louis, MO

RESULTS: In participants with acute ischemic stroke (AIS), the use of argatroban or eptifibatide and thrombolysis did not improve functional outcomes at 90 days but did not significantly increase symptomatic intracerebral hemorrhage compared to participants who received placebo and thrombolysis within three hours of symptom onset.

• MOST Data Summary (PDF)
• ClinicalTrials ID: NCT03735979
• AHA News Release: Blood thinners added to clot-busting medication did not improve stroke outcomes

#ISC24 Presidential Address

Joseph C. Wu, MD, PhD, FAHA, President of the American Heart Association, delivered the annual address to ISC24 attendees during the Opening Main Event on Wednesday, February 7, 2024. His address touched on the future of cardiovascular science and medicine.

GOLDEN BRIDGE II

Effect of an Artificial Intelligence-Based Clinical Decision Support System on Stroke Care Quality and Outcomes in Patients With Acute Ischemic Stroke (Golden Bridge II): A Cluster-Randomized Clinical Trial
Zixiao Li, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

RESULTS: In participants with acute ischemic stroke, compared to usual care, AI-CDSS (artificial intelligence-based clinical decision support system) demonstrated significantly fewer vascular events at 3 months and led to improvement in stroke care quality.

• GOLDEN BRIDGE II Data Summary (PDF)
• Published in Stroke and Vascular Neurology - Rationale and Design of the Golden Bridge II(link opens in new window)
• ClinicalTrials ID: NCT04524624
• AHA News Release: AI-based system to guide stroke treatment decisions may help prevent another stroke

EMBOLISE

Embolization of the Middle Meningeal Artery With Onyx Liquid Embolic System in the Treatment of Subacute and Chronic Subdural Hematoma
Jason Davies, University at Buffalo, Buffalo, NY

RESULTS: In participants with symptomatic subacute or chronic subdural hematoma (SDH), the addition of middle meningeal artery (MMA) embolization with Onyx™ resulted in nearly a 3-fold reduction in hematoma recurrence/progression requiring re-operation compared to surgery alone.

• EMBOLISE Data Summary (PDF)
• AHA News Release: Blocking artery supplying the brain covering after subdural hematoma reduced repeat surgery
• ClinicalTrials ID: NCT04402632

MAGIC-MT

Managing Non-Acute Subdural Hematoma Using Liquid Materials: A Chinese Randomized Trial of Middle Meningeal Artery Treatment
Ying Mao, Huashan Hospital, Fudan University, Shanghai, China

RESULTS: In participants with symptomatic non-acute subdural hematoma (SDH), the use of middle meningeal artery (MMA) embolization resulted in less hematoma recurrence and progression compared to standard care alone.

• MAGIC-MT Data Summary (PDF)
• ClinicalTrials ID: NCT04700345

STEM

The SQUID Trial for the Embolization of the MMA for the treatment of CSDH
Adam S Arthur, Semmes-Murphey Neurological Clinic, Memphis, TN

RESULTS: In participants with symptomatic chronic subdural hematoma (CSDH), the addition of middle meningeal artery embolization (MMAE) with SQUID™ resulted in reduced treatment failure rate compared to standard management alone.

• STEM Data Summary (PDF)
• ClinicalTrials ID: NCT04410146